Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea
Up next
Author


The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales in the process.

You May Also Like

BOJ board discussed future policy path at July meeting, summary shows

A summary of opinions given at the Bank of Japan’s last meeting…
Alphabet and Apple stocks rally after Google antitrust ruling avoids the worst-case scenario

Alphabet and Apple stocks rally after Google antitrust ruling avoids the worst-case scenario

Google can keep its Chrome browser and continue to enter in revenue-sharing…
20 value stocks primed for rapid revenue growth

20 value stocks primed for rapid revenue growth

This might be the perfect time to add exposure to value stocks,…
Nursing homes may start sedating your elderly parents — and, eventually, you — because they don’t have enough workers

Nursing homes may start sedating your elderly parents — and, eventually, you — because they don’t have enough workers

Staffing levels “significantly impact” the use of antipsychotic medication, new research has…